Genmab AS Stock Forward View
| GMAB Stock | USD 32.63 0.72 2.16% |
Genmab Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Genmab AS stock prices and determine the direction of Genmab AS's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Genmab AS's historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time, The RSI of Genmab AS's share price is at 51. This usually indicates that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling Genmab AS, making its price go up or down. Momentum 51
Impartial
Oversold | Overbought |
Quarterly Earnings Growth 1.076 | EPS Estimate Next Quarter 0.4033 | EPS Estimate Current Year 1.9118 | EPS Estimate Next Year 1.4878 | Wall Street Target Price 38.0714 |
Using Genmab AS hype-based prediction, you can estimate the value of Genmab AS from the perspective of Genmab AS response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Genmab AS using Genmab AS's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Genmab using crowd psychology based on the activity and movement of Genmab AS's stock price.
Genmab AS Short Interest
A significant increase or decrease in Genmab AS's short interest from the previous month could be a good indicator of investor sentiment towards Genmab. Short interest can provide insight into the potential direction of Genmab AS stock and how bullish or bearish investors feel about the market overall.
200 Day MA 26.4671 | Short Percent 0.0163 | Short Ratio 6.11 | Shares Short Prior Month 11.1 M | 50 Day MA 32.2982 |
Genmab Relative Strength Index
The Naive Prediction forecasted value of Genmab AS on the next trading day is expected to be 32.31 with a mean absolute deviation of 0.58 and the sum of the absolute errors of 35.22.Genmab AS Hype to Price Pattern
Investor biases related to Genmab AS's public news can be used to forecast risks associated with an investment in Genmab. The trend in average sentiment can be used to explain how an investor holding Genmab can time the market purely based on public headlines and social activities around Genmab AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Genmab AS's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Genmab AS.
Genmab AS Implied Volatility | 0.84 |
Genmab AS's implied volatility exposes the market's sentiment of Genmab AS stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Genmab AS's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Genmab AS stock will not fluctuate a lot when Genmab AS's options are near their expiration.
The Naive Prediction forecasted value of Genmab AS on the next trading day is expected to be 32.31 with a mean absolute deviation of 0.58 and the sum of the absolute errors of 35.22. Genmab AS after-hype prediction price | USD 32.46 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Genmab AS to cross-verify your projections. Prediction based on Rule 16 of the current Genmab contract
Based on the Rule 16, the options market is currently suggesting that Genmab AS will have an average daily up or down price movement of about 0.0525% per day over the life of the 2026-03-20 option contract. With Genmab AS trading at USD 32.63, that is roughly USD 0.0171 . If you think that the market is fully incorporating Genmab AS's daily price movement you should consider acquiring Genmab AS options at the current volatility level of 0.84%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-03-20 Genmab Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Genmab AS's spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Genmab AS's options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Genmab AS stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Genmab AS's open interest, investors have to compare it to Genmab AS's spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Genmab AS is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Genmab. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Genmab AS Additional Predictive Modules
Most predictive techniques to examine Genmab price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Genmab using various technical indicators. When you analyze Genmab charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Genmab AS Cash Forecast
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the Genmab AS's financial statements to predict how it will affect future prices.
Cash | First Reported 2009-12-31 | Previous Quarter 8.2 B | Current Value 1.8 B | Quarterly Volatility 4.5 B |
Genmab AS Naive Prediction Price Forecast For the 2nd of February
Given 90 days horizon, the Naive Prediction forecasted value of Genmab AS on the next trading day is expected to be 32.31 with a mean absolute deviation of 0.58, mean absolute percentage error of 0.56, and the sum of the absolute errors of 35.22.Please note that although there have been many attempts to predict Genmab Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Genmab AS's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Genmab AS Stock Forecast Pattern
| Backtest Genmab AS | Genmab AS Price Prediction | Buy or Sell Advice |
Genmab AS Forecasted Value
In the context of forecasting Genmab AS's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Genmab AS's downside and upside margins for the forecasting period are 30.11 and 34.51, respectively. We have considered Genmab AS's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Genmab AS stock data series using in forecasting. Note that when a statistical model is used to represent Genmab AS stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 117.5373 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.5773 |
| MAPE | Mean absolute percentage error | 0.018 |
| SAE | Sum of the absolute errors | 35.2173 |
Predictive Modules for Genmab AS
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Genmab AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Genmab AS After-Hype Price Density Analysis
As far as predicting the price of Genmab AS at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Genmab AS or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Genmab AS, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Genmab AS Estimiated After-Hype Price Volatility
In the context of predicting Genmab AS's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Genmab AS's historical news coverage. Genmab AS's after-hype downside and upside margins for the prediction period are 30.26 and 34.66, respectively. We have considered Genmab AS's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Genmab AS is very steady at this time. Analysis and calculation of next after-hype price of Genmab AS is based on 3 months time horizon.
Genmab AS Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Genmab AS is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genmab AS backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Genmab AS, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.23 | 2.20 | 0.17 | 0.46 | 11 Events / Month | 7 Events / Month | In about 11 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
32.63 | 32.46 | 0.52 |
|
Genmab AS Hype Timeline
Genmab AS is currently traded for 32.63. The entity has historical hype elasticity of -0.17, and average elasticity to hype of competition of 0.46. Genmab is forecasted to decline in value after the next headline, with the price expected to drop to 32.46. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.52%, whereas the daily expected return is currently at 0.23%. The volatility of related hype on Genmab AS is about 109.73%, with the expected price after the next announcement by competition of 33.09. The book value of the company was currently reported as 93.41. The company has Price/Earnings To Growth (PEG) ratio of 0.62. Genmab AS had not issued any dividends in recent years. The entity had 5:1 split on the 1st of May 2018. Given the investment horizon of 90 days the next forecasted press release will be in about 11 days. Check out Historical Fundamental Analysis of Genmab AS to cross-verify your projections.Genmab AS Related Hype Analysis
Having access to credible news sources related to Genmab AS's direct competition is more important than ever and may enhance your ability to predict Genmab AS's future price movements. Getting to know how Genmab AS's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Genmab AS may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| INCY | Incyte | 2.29 | 10 per month | 1.76 | 0.06 | 4.10 | (2.92) | 14.33 | |
| UTHR | United Therapeutics | 7.09 | 9 per month | 1.07 | 0.08 | 2.19 | (1.80) | 12.18 | |
| RPRX | Royalty Pharma Plc | (0.38) | 10 per month | 1.41 | 0.09 | 2.03 | (2.28) | 12.26 | |
| THC | Tenet Healthcare | 5.05 | 7 per month | 0.00 | (0.08) | 3.14 | (3.00) | 14.80 | |
| ILMN | Illumina | 5.21 | 10 per month | 1.36 | 0.17 | 4.19 | (2.83) | 28.04 | |
| DGX | Quest Diagnostics Incorporated | 0.13 | 11 per month | 1.14 | (0.02) | 2.68 | (1.96) | 6.29 | |
| ROIV | Roivant Sciences | 0.22 | 13 per month | 1.58 | 0.09 | 4.37 | (2.84) | 9.44 | |
| SMMT | Summit Therapeutics PLC | 0.04 | 12 per month | 0.00 | (0.11) | 5.41 | (5.97) | 23.61 | |
| ZBH | Zimmer Biomet Holdings | (0.55) | 8 per month | 0.00 | (0.12) | 2.92 | (2.20) | 18.45 | |
| EXEL | Exelixis | 0.95 | 10 per month | 1.75 | 0.01 | 4.06 | (2.93) | 11.45 |
Other Forecasting Options for Genmab AS
For every potential investor in Genmab, whether a beginner or expert, Genmab AS's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Genmab Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Genmab. Basic forecasting techniques help filter out the noise by identifying Genmab AS's price trends.Genmab AS Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genmab AS stock to make a market-neutral strategy. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Genmab AS Market Strength Events
Market strength indicators help investors to evaluate how Genmab AS stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Genmab AS shares will generate the highest return on investment. By undertsting and applying Genmab AS stock market strength indicators, traders can identify Genmab AS entry and exit signals to maximize returns.
Genmab AS Risk Indicators
The analysis of Genmab AS's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Genmab AS's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting genmab stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 1.65 | |||
| Semi Deviation | 2.03 | |||
| Standard Deviation | 2.14 | |||
| Variance | 4.57 | |||
| Downside Variance | 4.79 | |||
| Semi Variance | 4.12 | |||
| Expected Short fall | (1.71) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Genmab AS
The number of cover stories for Genmab AS depends on current market conditions and Genmab AS's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Genmab AS is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Genmab AS's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Genmab AS Short Properties
Genmab AS's future price predictability will typically decrease when Genmab AS's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Genmab AS often depends not only on the future outlook of the potential Genmab AS's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Genmab AS's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 646.3 M | |
| Cash And Short Term Investments | 21.1 B |
Check out Historical Fundamental Analysis of Genmab AS to cross-verify your projections. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. Market participants price Genmab higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Genmab AS assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 1.076 | Earnings Share 2.28 | Revenue Per Share | Quarterly Revenue Growth 0.174 | Return On Assets |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Genmab AS's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.